Data from a retrospective registry study investigated the efficacy and safety of the dual GIP‐GLP‐1RA Tirzepatide as adjunctive treatment in T1D patients with overweight or obesity, most having class III obesity (mean BMI of 41.2%) [81]. Here, GIP is linked to type 1 diabetes mellitus.